Daniel Larcombe-Young

420 total citations
7 papers, 180 citations indexed

About

Daniel Larcombe-Young is a scholar working on Oncology, Immunology and Neurology. According to data from OpenAlex, Daniel Larcombe-Young has authored 7 papers receiving a total of 180 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Immunology and 1 paper in Neurology. Recurrent topics in Daniel Larcombe-Young's work include CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (5 papers) and T-cell and B-cell Immunology (4 papers). Daniel Larcombe-Young is often cited by papers focused on CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (5 papers) and T-cell and B-cell Immunology (4 papers). Daniel Larcombe-Young collaborates with scholars based in United Kingdom, Italy and Saudi Arabia. Daniel Larcombe-Young's co-authors include John Maher, David M. Davies, Tamara Muliaditan, Paris Kosti, Cheryl Gillett, James W. Opzoomer, Rhonda Henley‐Smith, Cheryl L. Scudamore, Natalie Woodman and James N. Arnold and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Molecular Therapy.

In The Last Decade

Daniel Larcombe-Young

7 papers receiving 176 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Larcombe-Young United Kingdom 5 157 71 60 48 34 7 180
Olivia Sirpilla United States 5 161 1.0× 66 0.9× 54 0.9× 72 1.5× 42 1.2× 9 208
Yale S. Michaels Canada 8 112 0.7× 55 0.8× 39 0.7× 142 3.0× 44 1.3× 15 232
Nikolaos Gkitsas United States 8 155 1.0× 67 0.9× 34 0.6× 85 1.8× 51 1.5× 10 189
Alexis Cuffel France 6 105 0.7× 60 0.8× 34 0.6× 45 0.9× 20 0.6× 7 140
Daniel Ngai United States 4 161 1.0× 71 1.0× 51 0.8× 40 0.8× 48 1.4× 4 201
Youguo Long China 8 209 1.3× 125 1.8× 46 0.8× 69 1.4× 53 1.6× 10 243
Isabel Leung United States 6 145 0.9× 80 1.1× 46 0.8× 93 1.9× 34 1.0× 7 220
Markus Barden Germany 6 157 1.0× 69 1.0× 50 0.8× 46 1.0× 44 1.3× 9 174
Jonathan Boiarsky United States 3 157 1.0× 82 1.2× 26 0.4× 198 4.1× 22 0.6× 5 312
Elizabeth Jinks United Kingdom 6 91 0.6× 109 1.5× 21 0.3× 74 1.5× 19 0.6× 8 203

Countries citing papers authored by Daniel Larcombe-Young

Since Specialization
Citations

This map shows the geographic impact of Daniel Larcombe-Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Larcombe-Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Larcombe-Young more than expected).

Fields of papers citing papers by Daniel Larcombe-Young

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Larcombe-Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Larcombe-Young. The network helps show where Daniel Larcombe-Young may publish in the future.

Co-authorship network of co-authors of Daniel Larcombe-Young

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Larcombe-Young. A scholar is included among the top collaborators of Daniel Larcombe-Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Larcombe-Young. Daniel Larcombe-Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Larcombe-Young, Daniel, Fahima Kausar, Caroline Hull, et al.. (2024). Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell Reports Medicine. 5(11). 101827–101827. 12 indexed citations
2.
Hull, Caroline, Daniel Larcombe-Young, Roberta Mazza, et al.. (2024). Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner. Molecular Therapy. 32(7). 2373–2392. 18 indexed citations
3.
Davies, David M., et al.. (2024). Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy. Biology. 13(3). 196–196. 2 indexed citations
4.
Halim, Leena, Kushal Kumar Das, Daniel Larcombe-Young, et al.. (2022). Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. Frontiers in Immunology. 13. 836549–836549. 19 indexed citations
5.
Larcombe-Young, Daniel, et al.. (2022). Generation of human parallel chimeric antigen receptor (pCAR) T cells to achieve synergistic T cell co-stimulation. STAR Protocols. 3(2). 101414–101414. 3 indexed citations
6.
Kosti, Paris, James W. Opzoomer, Rhonda Henley‐Smith, et al.. (2021). Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Reports Medicine. 2(4). 100227–100227. 111 indexed citations
7.
Hoffmann, Ricarda M., Silvia Mele, Anthony Cheung, et al.. (2020). Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). Scientific Reports. 10(1). 8869–8869. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026